Waratah Pharmaceuticals Inc

Psyence Group Inc. is a life science biotechnology company based in Toronto, Ontario, focused on developing innovative, safe, and effective psychedelic and nature-centered solutions for mental health, particularly in the context of palliative care. The company specializes in natural psilocybin products and medicinal formulations aimed at treating anxiety, depression, and associated ailments within clinical environments. As one of the first federally licensed and ISO 22000 certified facilities for psilocybin cultivation and production, Psyence Group operates under the NASDAQ-listed entity Psyence Biomedical Ltd. The company's team comprises experts in neurology and pharmaceutical product commercialization, alongside a global executive team experienced in capital markets and sustainable growth. Generated from the website

Neural Therapeutics Inc. is an ethnobotanical drug discovery and development company dedicated to researching and developing products utilizing psychoactive plants, notably the San Pedro cactus (Echinopsis pachanoi), which contains mescaline. The company emphasizes the importance of indigenous knowledge in the effective use of whole plant extracts, aiming to honor traditional practices while advancing modern pharmaceutical and nutraceutical applications. With a focus on sustainable practices, Neural Therapeutics follows a research and development roadmap that seeks to create zero waste by fully utilizing the plant's capabilities. Comprised of an experienced leadership team with expertise in environmental science, pharmacology, and corporate finance, the company is well-positioned to explore innovative solutions in the natural products industry. Generated from the website

PharmAla Biotech Holdings Inc. is a Canadian biotechnology company focused on the research, development, and sourcing of clinical-grade LaNeo MDMA and novel MDXX compounds for the scientific research community and commercial use in select jurisdictions. The company aims to advance the medicinal use of MDMA by ensuring a steady supply of clinical-grade Active Pharmaceutical Ingredient (API) while also working on improving the safety properties of MDMA and its analogs. With a commitment to regulatory compliance and rigorous standards, PharmAla collaborates with top laboratories across Canada to develop novel processes for MDMA supply. As a leader in the psychedelics market, the company is uniquely positioned to address the growing demand for MDMA in research, having established the first legal commercial value chain for clinical-grade GMP LaNeo MDMA products in North America. Generated from the website